Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Inclusion Criteria: * Male and female subjects with surface antigen confirmed multiple myeloma with no available curative treatment options (including autologous or allogeneic SCT). * Complete remission (CR) cannot be achieved after at least 4 prior combination therapy regimens. * MM in CR2 or CR3 and not eligible for allogeneic SCT because of age, comorbid diseases, or lack of available donor. * Less than 1 year between last chemotherapy and progression (i.e. most recent progression free interval \< 1 year). * Relapsed after prior autologous or allogenic SCT MM patients with relapsed or residual disease after at least 1 prior therapy and not eligible for allogeneic SCT. * Residual disease after primary therapy and not eligible for ASCT * Expected survival \> 12 weeks * Creatinine \< 2.5 mg/dl * ALT (alanine aminotransferase)/AST (aspartate aminotransferase) \< 3x normal * Bilirubin \< 2.0 mg/dl * Any relapse after prior SCT is eligible regardless of other prior therapy * Adequate venous access for apheresis, and no other contraindications for leukapheresis * Voluntary informed consent is given Exclusion Criteria: * Pregnant or lactating women * Uncontrolled active infection * Active hepatitis B or hepatitis C infection * Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary. * Previous related CAR-T cell therapy Any uncontrolled active medical disorder that would preclude participation * HIV infection